*NOVO NORDISK STARTS MULTI-MONTH SUBSCRIPTION PROGRAM FOR WEGOVY
$NVO https://t.co/mM14BZXQB3
@Investingcom
*NOVO AND HIMS END FEUD, WILL SELL OBESITY DRUGS TOGETHER
$NVO $HIMS https://t.co/RvbLhOWfuZ
@Investingcom
*NOVO NORDISK TO CUT OZEMPIC, WEGOVY'S US LIST PRICES BY UP TO 50%: WSJ
$NVO https://t.co/fBJ05M6MNr
@Investingcom
STARTS NOW! Rebel's Edge 1pm 🕐 $VNDA $ACLX $NVO $DPZ 🏈 NAJARIAN SPORTS 🏴☠️ with @petenajarian Winter Olympics: Hockey Finals was scripted perfectly, but did it reach 1980 levels? NFL: Chicago Bears, will they need to change the team's name? Indiana looking to build a Dome, NW https://t.co/CUnDFsQQz7
@MarketRebels
*NOVO NORDISK SINKS 15% AFTER WEIGHT LOSS DRUG FAILS TO MATCH ELI LILLY'S IN TRIAL
$NVO $LLY https://t.co/xRsnosJ0yS
@Investingcom
4 stocks to watch on Monday: LLY, NVO, APO, TTE
SeekingAlpha
*NOVO NORDISK SHARES SINK AFTER SALES OUTLOOK MISSES FORECAST
$NVO https://t.co/NYcHbsSOue
@Investingcom
📅IT’S A BIG WEEK OF EARNINGS!
📈 $GOOGL $AMZN $AMD $PLTR $QCOM $ARM $SMCI $RDDT $RBLX $SNAP $PYPL $AFRM $UBER $DIS $PEP $CMG $TSN $LLY $NVO $PFE $MRK $COP $SHEL $B WILL DELIVER RESULTS!
💰MAKE SMARTER INVESTMENT DECISIONS WITH ‘PRO PICKS AI’:
🎁GET 50% OFF ALL PRO PLANS FOR https://t.co/hCLP39WM0n
@Investingcom
4 stocks to watch on Monday: NVO, PANW, OKTA, TWLO
SeekingAlpha
*NOVO NORDISK EXTENDS GAIN TO 10% AS WEGOVY PILL APPROVED IN US
$NVO https://t.co/HTqEikpfvR
@Investingcom
*NOVO NORDISK SHARES PLUNGE 10% AFTER ALZHEIMER’S DRUG TRIAL FAILS TO HIT KEY TARGET
$NVO https://t.co/TRBNffy1K5
@Investingcom
STARTS NOW! Rebel's Edge 🏴☠️ 1pm Stocks $DAY $NVO $WULF $EQT 🏈NAJARIAN SPORTS with @petenajarian Best Week 1, 2, 3 of College Football Biggest schools playing each other Heisman way to early read: I have a dark horse, but Arch is sitting at the top https://t.co/j2t4k86P3o
@MarketRebels
*NOVO NORDISK SHARES PLUNGE 20% AFTER CUTTING FULL-YEAR GUIDANCE, NAMING NEW CEO
$NVO https://t.co/xg8Nvsv4mD
@Investingcom
*NOVO NORDISK CEO TO STEP DOWN IN A SURPRISE MOVE
$NVO https://t.co/JVN0yjXC6c
@Investingcom
Premarket Mover: $CVS +8%
✅ Q1 beats on top & bottom line
🛑 Exiting individual ACA insurance (#Obamacare)
🤝 Teams up with $NVO to boost access to weight-loss drug #Wegovy https://t.co/i9HgDC7DhN
@SeekingAlpha
Shares of Hims & Hers Health $HIMS are up double digits after the telehealth company announced a partnership with Novo Nordisk $NVO to sell the Danish drugmaker’s popular weight loss therapy, Wegovy.
#Wegovy #WeightLoss #Healthcare #MarketWatch https://t.co/P3l230QDgw
@SeekingAlpha
*NOVO NORDISK’S DIABETES PILL SLASHES RISK OF CARDIOVASCULAR COMPLICATIONS BY 14% AFTER FOUR YEARS
$NVO https://t.co/aUPHWSp1f5
@Investingcom
Novo Nordisk reported full-year revenue of $40.5B, up 25% compared to 2023 Wednesday.
For Q4 $NVO reported $11.6B in revenues, up 30% compared to the same quarter in 2023.
The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic for diabetes, were key… https://t.co/lTuClsWXaK https://t.co/7h4Uvwelz2
@YahooFinance
⚠️ JUST IN:
*NOVO NORDISK BEATS EARNINGS ESTIMATE AS WEGOVY WEIGHT LOSS DRUG SALES JUMP 107% IN Q4
$NVO +3.6% https://t.co/vtyL7vyC4H
@Investingcom
🎉ANOTHER BIG EARNINGS WEEK IS UPON US!
💰 $GOOGL $AMZN $AMD $ARM $QCOM $PLTR $SNAP $DIS $PYPL $LLY $PFE $MRK $NVO $UBER $F $RACE $TM $PEP $CMG ARE ALL SET TO DELIVER RESULTS!
📈PLAN EARLY WITH ALL KEY DATA IN 1 PLACE: https://t.co/Zh3sZIRv6K 👈 https://t.co/0Zont0zt9H https://t.co/JTwOtijLxx
@Investingcom
"Denmark stock market -20% since Sept 24 driven by Novo Nordisk -40%... NVO was 60% of stock market; best reminder of concentration risk" - BofA's Hartnett https://t.co/QMb8bJr6A4
@zerohedge
⚠️BREAKING:
*NOVO NORDISK STOCK PLUNGES 16% AFTER WEIGHT-LOSS DRUG DATA DISAPPOINTS; RIVAL ELI LILLY JUMPS 5%
$NVO $LLY https://t.co/3v081kCR1V
@Investingcom
STARTS NOW! Rebel's Edge 🏴☠️1pm line up: Fed speak 🗣️ and ongoing inflation concerns. $NVO $PARA $TSLA $ARDX Sports @petenajarian 🏈 #NFL Sleeper team for NFC Atlanta, if Cousins is healthy, that offense will roll https://t.co/W9YiylSHZi
@MarketRebels
⚠️ JUST IN:
*NOVO NORDISK SHARES JUMP 4% TO HIT NEW RECORD HIGH AS WEGOVY GETS APPROVAL IN CHINA
ARE YOU BUYING OR SELLING?
$NVO https://t.co/n5ugypCcym
@Investingcom
⚠️ JUST IN:
*NOVO NORDISK TOPS EARNINGS ESTIMATE, RAISES OUTLOOK FUELLED BY SOARING OBESITY DRUG DEMAND
$NVO https://t.co/h8x2y31Zhg
@Investingcom
⚠️BREAKING:
*NOVO NORDISK STOCK SOARS TO A NEW RECORD AS IT TOUTS THE POTENTIAL OF ITS NEXT-GEN OBESITY TREATMENTS
$NVO https://t.co/wHxSn00a1w
@Investingcom
⚠️ JUST IN:
*NOVO NORDISK, THE OBESITY DRUG MAKER, BECOMES THE SECOND-EVER EUROPEAN COMPANY TO REACH A $500 BILLION MARKET VALUE
$NVO https://t.co/AzkbwhSOP7
@Investingcom
⚠️BREAKING:
*NOVO NORDISK’S WEIGHT LOSS DRUG WEGOVY SLASHES RISK OF SERIOUS HEART EVENTS, INCLUDING HEART ATTACK AND STROKE
$NVO https://t.co/zpTx6CWWar
การลงทุนในหุ้นต้องการการวิจัยอย่างละเอียด รวมถึงการวิเคราะห์ข้อมูลทางการเงินของบริษัท ข่าวที่เกี่ยวข้อง และการวิเคราะห์ทางเทคนิค ปัจจุบันคำแนะนำจากนักวิเคราะห์ทางเทคนิคของ Tesla แสดงให้เห็นว่าเป็นการให้คะแนน hold